Navigation Links
Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
Date:10/24/2007

ROCHESTER, Minn. -- A new Mayo Clinic study due to be presented at the annual meeting of the American Society of Human Genetics in San Diego this week shows that a chromosome test called FISH is better than conventional methods in identifying chromosomal genetic abnormalities associated with plasma cell malignancies. This improved chromosomal analysis may help physicians better assess a patients prognosis and likelihood to respond to a given treatment.

Plasma cell proliferative disorders, or PCPD, account for approximately 10 percent of all blood born cancers that range from the very slow-growing smoldering myeloma to a very aggressive plasma cell leukemia.

The study will be presented by Ryan Knudson of the Mayo Clinic Cytogenetics Laboratory at 6:30 p.m., CDT, Wednesday, Oct. 24.

FISH, which stands for fluorescence in situ hybridization, detected chromosomal abnormalities in 67 percent of 1,548 patients with suspected PCPD. Conventional chromosomal analysis detected abnormalities in only 10 percent of the same patients. The FISH test is designed to detect genetic abnormalities in plasma cells whereas other conventional methods typically looks within any cell type that is present, says the lead author of the study, Rhett Ketterling, M.D., a Mayo Clinic pathologist and geneticist who specializes in chromosomes and chromosomal abnormalities.

This test is a marked improvement over conventional chromosomal analysis and has become readily accepted into the diagnostic algorithm in patients with PCPD at Mayo Clinic and at other leading academic institutions, Dr. Ketterling says.

The test should be applied to patients diagnosed with PCPD, particularly multiple myeloma, to determine the presence of genetic abnormalities that could offer insight into prognosis, he states.

Our results show that a targeted plasma-cell specific FISH analysis is an important method for detecting common genetic abnormalities typically seen in patients with multiple myeloma, Dr. Ketterling says.


'/>"/>

Contact: Amy Reyes
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. WHO Gives Its Approval For Bird Flu Test Kit
2. Microchip gives blind a chance of sight
3. Microchip gives blind a chance of sight
4. Combined scan gives exact cancer diagnosis
5. Tennis gives protection against heart disease lifelong
6. Camera gives hope for detection of breast cancer
7. Pancreas transplant gives hope to type 2 diabetes
8. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
9. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
10. FDA gives “black box warning” against three asthma drus
11. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
Breaking Medicine Technology: